Mutations causing complex disease may under certain circumstances be protective in an eidemiological sense by Siegert, Sabine et al.
RESEARCH ARTICLE
Mutations Causing Complex Disease May
under Certain Circumstances Be Protective in
an Epidemiological Sense
Sabine Siegert1,2, AndreasWolf3, David N. Cooper4, Michael Krawczak3‡,
Michael Nothnagel1,3‡*
1 Cologne Center for Genomics, University of Cologne, Cologne, Germany, 2 Institute of Epidemiology,
Christian-Albrechts University, Kiel, Germany, 3 Institute of Medical Informatics and Statistics, Christian-
Albrechts University, Kiel, Germany, 4 Institute of Medical Genetics, School of Medicine, Cardiff University,
Cardiff, United Kingdom
‡ These authors are joint senior authors on this work.
* michael.nothnagel@uni-koeln.de
Abstract
Guided by the practice of classical epidemiology, research into the genetic basis of complex
disease has usually taken for granted the dictum that causative mutations are invariably
over-represented among clinically affected as compared to unaffected individuals. How-
ever, we show that this supposition is not true and that a mutation contributing to the etiol-
ogy of a complex disease can, under certain circumstances, be depleted among patients.
Populations with defined disease prevalence were repeatedly simulated under a Wright-
Fisher model, assuming various types of population history and genotype-phenotype rela-
tionship. For each simulation, the resulting mutation-specific population frequencies and
odds ratios (ORs) were evaluated. In addition, the relationship between mutation frequency
and OR was studied using real data from the NIH GWAS catalogue of reported phenotype
associations of single-nucleotide polymorphisms (SNPs). While rare diseases (prevalence
<1%) were found to be consistently caused by rare mutations with ORs>1, up to 20% of
mutations causing a pandemic disease (prevalence 10–20%) had ORs<1, and their popula-
tion frequency ranged from 0% to 100%. Moreover, simulation-based ORs exhibited a wide
distribution, irrespective of mutation frequency. In conclusion, a substantial proportion of
mutations causing common complex diseases may appear ‘protective’ in genetic epidemio-
logical studies and hence would normally tend to be excluded, albeit erroneously, from fur-
ther study. This apparently paradoxical result is explicable in terms of mutual confounding
of the respective genotype-phenotype relationships due to a negative correlation between
causal mutations induced by their common gene genealogy. As would be predicted by our
findings, a significant negative correlation became apparent in published genome-wide
association studies between the OR of genetic variants associated with a particular disease
and the prevalence of that disease.
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Introduction
In the past decade, a large number of genome-wide association studies (GWAS) have been
undertaken in order to dissect the genetic basis of complex diseases [1,2]. Indeed, since the first
such study was published in 2005 [3], more than 1200 susceptibility loci for>165 common
human diseases have been identified by GWAS [4–6]. Although most of the genotype-pheno-
type associations reported from GWAS were modest at best, even if successfully replicated
[4,7], and often involved variants located outside functionally relevant gene regions, these stud-
ies have nevertheless provided important new insights into the etiology of complex human dis-
eases [4,8]. This notwithstanding, genetic risk factors hitherto identified by GWAS usually
account for only a small fraction of the heritability of the disease in question. Indeed, for the
vast majority of conditions studied,>90% of the population-level phenotypic variation has
remained unaccounted for by reference to any known genetic variation [6,9]. Several explana-
tions for this outcome have been put forward, including a major role for rare as yet unidentified
variants, structural features such as copy-number variation (CNVs), power loss due to exces-
sive multiple testing, locus and allelic heterogeneity, parent of origin effects and gene-gene as
well as gene-environment interactions [4,5,10,11].
In addition, a number of sometimes counterintuitive phenomena have been described to
occur in the context of genetic disease associations. For example, risk alleles often change their
role from predisposing to protective and vice versa in different populations, thereby spawning
so-called ‘flip-flop associations’ that probably reflect gene-gene interaction and differential
linkage disequilibrium [12]. Moreover, a ‘synthetic association’ [13] between a disease and a
common non-causative variant can arise as a consequence of the chance accumulation of sev-
eral rare causative variants in cis to the latter [14–16]. Finally, it has been demonstrated by sim-
ulation that, in multi-locus systems of correlated causal and non-causal genetic factors, an
‘indirect association’ between a non-causal variant and a disease can arise even in the absence
of any causative genes in the vicinity [17].
Here, we report a population history mechanism that may obfuscate the causal relationship
between a genetic variant and a (common) human disease. In classical epidemiology, making
inference about disease causation is usually equivalent to ascertaining whether or not a given
exposure confers a relative risk greater than unity. However, this process of reasoning (also
enshrined in the concept of ‘attributable fractions’ [18]) may be confounded by other unmea-
sured causal factors. In particular, a causative exposure may pose as a protective factor rather
than a risk factor if it is negatively correlated with its causal complement, defined as those
other risk factors or combinations of risk factors that are both necessary and sufficient for the
exposure in question to cause disease [18]. In genetic epidemiology, genotypes play the role of
risk factors and, since many human diseases follow a complex oligogenic or polygenic mode of
inheritance [19], causal complementation is probably omnipresent (see Fig 1). Moreover, all
humans share a common genealogy which induces varying levels of inter- and intra-individual
dependency between genotypes [20].
In view of the above, any uncritical adoption of the paradigm from classical epidemiology
that disease-causing genetic variants should invariably be over-represented in the clinically
affected portion of the population under study (i.e. that they confer a relative disease risk
exceeding unity) [21] may be misleading. In fact, we show by simulation that, depending upon
the specifics of the genealogy of the population of interest, a causative mutation may well
appear “protective” in an epidemiological sense. Normally, the functional follow-up of such a
variant would end up being inconclusive simply because its damaging character would be
difficult to reconcile with its protective effect. In many instances, the variant would then be
erroneously excluded from further consideration. In order to lend additional support to our
Misreading Effect Measures in Genetic Epidemiology
PLOS ONE | DOI:10.1371/journal.pone.0132150 July 10, 2015 2 / 21
conclusions, we also present empirical evidence for the presence, in real GWAS, of an inverse
relationship between epidemiological effect size and disease prevalence as would be predicted
by the above mechanism of confounding.
Fig 1. Illustration of a genealogy-actuated negative correlation between causative mutations. The underlying penetrance model assumes that two or
more causative mutations are required for an individual to become affected (with certainty). The blue mutation is depleted among affected individuals in this
population of four and, therefore, is protective in an epidemiological sense. The other mutations are enriched in cases.
doi:10.1371/journal.pone.0132150.g001
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Materials and Methods
Simulations
We investigated various models of population history and penetrance to determine the impact
upon epidemiological effect size of a genealogy-related negative correlation between disease-
causing mutations. To this end, we repeatedly simulated the genealogy of a population of con-
stant size (N = 10,000) following a coalescent approach [22]. The coalescent is a well-estab-
lished means of modeling population histories which, compared to forward-time simulation, is
both easier to implement and computationally more efficient [23]. We initially adopted a
Wright-Fisher model [24] of a single haploid locus was initially adopted in order to model the
evolution of functionally relevant variation within genes or gene regions small enough to
escape internal meiotic recombination. Subsequently, we extended our simulations to oligo-
genic models of inheritance involving 2, 5 or 10 unlinked and hence independently evolving
loci in order to assess the possible influence of recombination on our results as well. After the
simulation of each locus-specific genealogy, causative mutations were randomly placed on the
branches of each coalescence tree with probabilities proportional to the respective branch
lengths.
Once all locus-specific trees and the distribution of mutations on the trees had been deter-
mined in a given simulation, each leaf (i.e. haploid individual) was randomly assigned a dichot-
omous disease state with probability P(k), where k denotes the number of causative mutations
present at all loci combined. We considered two biologically plausible penetrance models that
have been widely used for similar analyses before [25–27]. More specifically, we used a one-
parameter multiplicative model (Fig 2A),
PðkÞ ¼ 1 ð1 gÞk with 0 < g < 1; ð1Þ
Fig 2. Disease risk as a function of the number of mutations present under two different penetrance models. (A) Multiplicative model with parameter γ
= 0.3 (blue) or γ = 0.1 (red). (B) Logistic model with parameters α = -5; β = 1 (blue) or α = -5; β = 0.5 (red).
doi:10.1371/journal.pone.0132150.g002
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which implies a steep increase in disease probability with increasing mutation number, and a
two-parameter logistic model (Fig 2B),
logit½PðkÞ ¼ aþ b  k with b > 0; ð2Þ
invoking tolerance against a small number of mutations. Both the multiplicative model and the
logistic model assume that mutations exert their additive effects on the respective scale. How-
ever, whereas individuals lacking a mutation (i.e. k = 0) would be unaffected under the multi-
plicative model, their (baseline) risk equals 1/(1+e-α)>0 under the logistic model. For both
models, we chose parameter values inducing either a strong or a weak increase in disease prob-
ability with mutation number.
We also modeled oligogenic disease etiologies that involved 2, 5 or 10 unlinked loci (e.g.
genes on different chromosomes), respectively. Since unlinked loci evolve essentially indepen-
dently in outbred populations, they also have nearly independent genealogies [28]. For this rea-
son, we repeatedly simulated the unrelated history of 2, 5 or 10 haploid loci, respectively, and
randomly assigned each individual a dichotomous disease state with probability P({k1,. . .,km}),
where ki denotes the number of causative mutations at the i-th locus. Again, we considered
both a multiplicative model,
Pðfk1; . . . ; kmgÞ ¼ 1 ð1 gÞ
Pm
i¼1ki with 0 < g < 1 ð3Þ
and a logistic model,
logit½Pðfk1; . . . ; kmgÞ ¼ aþ b 
Pm
i¼1ki with b > 0; ð4Þ
both of which assume the same contribution to the disease risk by allm loci. Only those simula-
tions with disease prevalence within a pre-speciﬁed range were selected for further analysis.
Simulations were repeatedly performed until 1,000 such datasets had been obtained per preva-
lence range. For each dataset, the mutation-speciﬁc population frequencies and odds ratios
(ORs) were calculated, except for those mutations that were exclusively present in either cases
or controls. Simulations were carried out with in-house scripts for Perl and R (S1 File). We
used R v3.0.3 [29] for statistical analysis and for creating graphs.
Analysis of GWAS data
In order to investigate whether the results of our inevitably simplifying simulations were con-
sistent with real data, we scrutinized the phenotype associations of single-nucleotide polymor-
phisms (SNPs) compiled in the NIH GWAS catalogue [30] (http://www.genome.gov/
26525384). Of the 14,869 records logged as of 13 November 2013, some 3,479 contained com-
plete information on the trait-associated SNP allele, the minor allele frequency (MAF), OR and
statistical significance (i.e. the p value). We merged reports with synonymous trait names (S1
Table) and, in order to improve data quality, we considered further only those traits for which
at least 10 (not necessarily different) significant SNP associations (p<5×10−8) had been
reported. Only traits of known prevalence in adults (>18 years) were included in our analysis.
We adopted two different significance thresholds for our analysis, namely (i) p<5×10−4 in at
least one GWAS to cover SNPs with small MAF and consequently low detection power, and
(ii) p<5×10−8 which is generally deemed to constitute genome-wide significance. In order to
minimize reporting bias, we initially considered only traits with prevalence between 0.1% and
20%. Later, we also included traits with prevalence<0.1% or adopted a maximum prevalence
of 15% (S2 Table). We used the incidence rate as an approximation for prevalence in the case
of the ‘sudden cardiac arrest’ trait. ORs were consistently considered to refer to the minor allele.
Subsequently, we confined our analysis to those associations for which the derived allele of the
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involved SNP could be identified unambiguously, thereby accounting for the fact that all dele-
terious mutations in our simulations were introduced anew (S2 Table). The necessary ancestral
allele information was retrieved from dbSNP (ftp://ftp.ncbi.nlm.nih.gov/snp/database/; down-
loaded May 27, 2015). In addition, we chose to consider only SNPs with unambiguous allele
assignment, i.e. SNPs with allele combinations A/T and C/G were excluded. Linear regression
analysis of the trait-specific OR (or median ORs) and the trait prevalence was carried out with
R v3.0.3 and the statistical significance of non-zero regression coefficients assessed using a
Wald test.
Results
As in previous studies [25–27], we employed simplified models of population history for the
coalescent simulation [22] and considered two types of combined penetrance, namely multipli-
cative or logistic. Although these two penetrance models are reminiscent of classical
approaches to the study of discontinuous multifactorial traits, including Falconer’s threshold
model [31], they are nevertheless different in that their affection probabilities are linked to
mutation number in quantitative (i.e. via a mathematical function) rather than qualitative fash-
ion (i.e. through a fixed threshold). Our analysis was stratified into three archetypal disease
prevalence ranges, namely rare (0.1% to 1%), common (1% to 5%) and pandemic (5% to 20%).
The simulations were carried out for both a single-locus and a two-locus model, where the lat-
ter was adopted to explore the possible effect of meiotic recombination on our conclusions.
Under a multiplicative penetrance model precluding tolerance to a small number of muta-
tions (Fig 2A), mutations at a single locus causing a rare disease (prevalence: 0.1-1.0%) were
consistently found to have ORs greater than unity (Fig 3A), and to be themselves rare (Fig 4A).
Virtually all mutations would be deemed to be disease-predisposing in this scenario because
controls were rarely carriers (median number of mutations per control: 0.054 for γ = 0.3; 0.013
for γ = 0.1; Table 1). By contrast, mutations causing a common disease (prevalence: 1–5%)
occasionally had OR<1 (up to 2.5% of simulations; Table 2 and Fig 3B), and many mutations
occurred at a frequency>50% (Fig 4B). By contrast, for pandemic diseases (prevalence: 10–
20%), a substantial proportion of causative mutations (up to 20% of simulations; Table 2) were
characterized by OR<1 (Fig 3C), rendering these mutations “protective” in an epidemiological
sense despite the lack of tolerance against a small number of causative mutations. Note that,
even though several dozens of mutations may have been present in the population as a whole,
the number of mutations per individual was consistently small (Table 1). The mutation fre-
quencies were found to span the whole range between 0% and 100% (Fig 4C), and the median
number of mutations present per case and present per control differed by less than threefold
(Table 1).
Under a logistic penetrance model invoking tolerance to a small number of mutations (Fig
2B), many more mutations than under a multiplicative model were required for the disease to
occur (Table 1). Thus, the median number of mutations per case ranged from 6 for a rare dis-
ease (α = -5; β = 1) to 74 for a pandemic disease (α = -5; β = 0.5). At least for rare diseases, the
discrepancy between the median numbers of mutations per case and per control was also
much smaller than under a multiplicative model (Table 1), an effect that was mainly attribut-
able to the non-zero baseline risk of the logistic model. In summary, the proportion of muta-
tions with ORs<1 was found to be higher under a logistic model (up to 34%; Fig 3D–3F,
Table 2) than under a multiplicative model for all prevalence ranges considered in our study,
and ORs were more widely distributed irrespective of the individual mutation frequency (Fig
4D–4F).
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Analyses of pairs of unlinked (i.e. freely recombining) loci yielded results similar to those of
the single-locus analysis (Figs 5 and 6). In fact, the median number of mutations per
Fig 3. Epidemiological effect size of causative mutations at a single locus under two different penetrance models. The distribution of the log10 odds
ratio (log10OR) is depicted for prevalence 0.1%-1.0% (A,D), 1%-5% (B,E) or 10%-20% (C,F), adopting either a multiplicative (A,B,C) or a logistic penetrance
model (D,E,F). Blue: multiplicative model parameter γ = 0.3, logistic model parameters α = -5; β = 1; Red:γ = 0.1, α = -5; β = 0.5.
doi:10.1371/journal.pone.0132150.g003
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population, per case and per control remained virtually unchanged under both penetrance
models and in all three prevalence categories (Table 3). However, the proportion of mutations
with OR<1 was substantially reduced, particularly in instances of high prevalence and MAF
(Table 4). This notwithstanding, the simulations revealed that, even with two unlinked loci
Fig 4. Relationship between epidemiological effect size (log10OR) and frequency of causativemutations at a single locus under two different
penetrance models. Prevalence 0.1%-1.0% (A,D), 1%-5% (B,E) or 10–20% (C,F); multiplicative model with γ = 0.1 (A,B,C), logistic model with α = -5; β =
0.5 (D,E,F).
doi:10.1371/journal.pone.0132150.g004
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contributing to the etiology of a given pandemic disease, up to 20% of mutations of at least
moderate epidemiological effect size (OR>1.5 or OR<1/1.5) may still appear “protective”
(Table 4). Simulations involving 5 or 10 unlinked loci (S1, S2, S3, S4 Figs and S3, S4, S5, S6
Tables) yielded smaller albeit still substantial proportions of apparently protective mutations.
Simultaneous consideration of larger numbers of loci unfortunately turned out to be computa-
tionally prohibitive. However, the emerging trend (Fig 7) indicates that even polygenic diseases
may feature a non-negligible proportion of causative mutations that appear protective in an
epidemiological sense.
One predicted consequence of our findings would be that the effect size of disease-associ-
ated genetic variants should be negatively correlated with the prevalence of the respective trait.
For example, simulation with a single causative locus and a logistic penetrance model (α = -5;
β = 0.5) yielded median ORs (median log10ORs) of 1.84 (0.26), 1.61 (0.21) and 1.50 (0.18) for a
rare, common and pandemic diseases, respectively (Fig 4D–4F). To test this prediction empiri-
cally, traits with at least 10 published genotype-phenotype associations at p<5×10−8 listed in
the GWAS catalogue [30] were scrutinized for variants that had both an OR and the MAF
reported (S2 File). When we focused upon those 31 traits with reliable prevalence information
(range: 0.1% to 20%), a total of 1834 associations with p<5×10−4 became available for analysis
(S2 Table). These data indeed revealed a statistically significant trend towards smaller ORs
with increasing prevalence (p<10−15 for single-variant ORs and p = 0.049 for phenotype-
wise median ORs, respectively; Fig 8). This observation was robust in the sense that it did
not depend upon a few particularly prevalent clinical phenotypes. Confining the analysis to
Table 1. Spectrum of causative mutations at a single locus arising under two different penetrancemodels.
Model parameters Median number of mutations (IQR)
Per population Per case Per control
Rare disease (prevalence: 0.1–1%)
Multiplicative
γ = 0.3 3 (2–5) 1.000 (1.000–1.000) 0.013 (0.007–0.019)
γ = 0.1 5 (3–7) 1.000 (1.000–1.000) 0.054 (0.030–0.076)
Logistic
α = -5; β = 1 6 (3–9) 0.407 (0.202–0.552) 0.177 (0.086–0.264)
α = -5; β = 0.5 9 (5–15) 0.876 (0.678–1.051) 0.638 (0.467–0.805)
Common disease (prevalence: 1–5%)
Multiplicative
γ = 0.3 5 (4–8) 1.000 (1.000–1.045) 0.081 (0.049–0.103)
γ = 0.1 9 (5–13) 1.098 (1.006–1.370) 0.367 (0.254–0.434)
Logistic
α = -5; β = 1 19 (13–28) 2.221 (1.996–2.449) 1.469 (1.267–1.655)
α = -5; β = 0.5 41 (29–56) 4.335 (4.079–4.608) 3.533 (3.262–3.746)
Pandemic disease (prevalence: 10–20%)
Multiplicative
γ = 0.3 11 (7–16) 1.241 (1.060–1.622) 0.442 (0.366–0.505)
γ = 0.1 24 (16–35) 2.391 (2.127–2.730) 1.877 (1.688–1.987)
Logistic
α = -5; β = 1 37 (26–52) 3.979 (3.741–4.318) 2.836 (2.551–3.068)
α = -5; β = 0.5 74 (54–98) 7.617 (7.351–8.026) 6.346 (5.980–6.634)
IQR: inter-quartile range
doi:10.1371/journal.pone.0132150.t001
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associations of genome-wide significance (p<5×10−8, 31 traits, 1298 associations) did not
change this trend (p = 1.9×10−6 and p = 0.051, respectively), which also remained when traits
with prevalence<0.1% were included (43 traits, 2178 associations, p<10−15 and p = 0.01,
respectively) or when the prevalence was confined to values<15% (30 traits, 1809 associations,
p<10−15 and p = 0.01, respectively). Finally, confining the analysis to those 1418 SNPs associ-
ated with a trait with a prevalence ranging from 0.1% to 20% and where the derived allele could
be identified unambiguously (S2 Table) also revealed a trend towards lower ORs with increas-
ing prevalence even although this result failed to attain statistical significance (p = 0.38 and
p = 0.71, respectively; S5 Fig).
Discussion
In those genetic epidemiological studies that are based upon statistical genotype-phenotype
relationships alone, drawing causal inference from ORs can be problematic for common and
pandemic complex diseases for which the presence of a particular mutation is rarely necessary
(let alone sufficient). Indeed, our simulation-based analyses revealed that causative inherited
mutations may well be more frequent in the clinically unaffected than in the affected portion of
a population, thereby rendering them “protective” rather than predisposing for these diseases
in an epidemiological sense. This counterintuitive phenomenon results from confounding of
the disease association of one mutation by the absence of other mutations necessary for the for-
mer to exert its effect in a given individual.
Table 2. Proportion of epidemiologically protective mutations at a single locus under two different penetrance models.
Model parameters Percentage mutations with OR<1.0 Percentage mutations with
OR>m or OR<1/m (percentage
of these with OR<1)
Percentage mutations with OR<1.0
among those with frequency <f
m = 1.5 m = 2.0 f = 0.001 f = 0.01 f = 0.05
Rare disease (prevalence: 0.1–1%)
Multiplicative
γ = 0.3 0.00 100.0 (0.00) 100.0 (0.00) 0.00 0.00 0.00
γ = 0.1 0.00 100.0 (0.00) 99.97 (0.00) 0.00 0.00 0.00
Logistic
α = -5; β = 1 4.04 89.07 (1.29) 74.91 (0.50) 0.00 0.00 5.12
α = -5; β = 0.5 14.20 67.25 (6.57) 46.61 (3.69) 0.00 0.00 12.84
Common disease (prevalence: 1–5%)
Multiplicative
γ = 0.3 0.00 99.92 (0.00) 99.81 (0.00) 0.00 0.00 0.00
γ = 0.1 1.25 95.95 (0.23) 90.84 (0.03) 0.00 2.50 1.71
Logistic
α = -5; β = 1 21.05 76.75 (15.53) 63.05 (12.06) 0.00 13.55 18.72
α = -5; β = 0.5 29.41 69.40 (23.25) 49.64 (18.86) 0.00 19.03 25.50
Pandemic disease (prevalence: 10–20%)
Multiplicative
γ = 0.3 1.94 93.51 (0.57) 83.49 (0.30) 4.15 3.66 2.59
γ = 0.1 20.23 67.16 (13.56) 46.35 (10.44) 12.12 20.92 20.44
Logistic
α = -5; β = 1 29.81 80.58 (25.28) 64.11 (21.73) 9.60 24.21 27.07
α = -5; β = 0.5 34.38 72.01 (30.63) 54.37 (27.71) 12.57 29.32 32.19
OR: odds ratio
doi:10.1371/journal.pone.0132150.t002
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A negative correlation between causative mutations can potentially arise due to the tree
structure of the human gene genealogy. More specifically, causative mutations that occur early
on in the history of a given population will be wide-spread but still have to accumulate other,
mostly younger mutations on the same haplotype for disease to occur in the current
Fig 5. Epidemiological effect size of causative mutations at two unlinked loci under two different penetrancemodels. See legend to Fig 3 for details.
doi:10.1371/journal.pone.0132150.g005
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generation. Younger mutations, on the other hand, are confined to different sub-trees so that
their co-occurrence with one another is less likely at the population level. As a net result, some
mutations, both old and young, may end up at the tips of sub-trees poor in complementing
(younger) mutations. Under the penetrance models employed here, such a negative correlation
is more likely to become evident for common and pandemic diseases than for rare diseases
Fig 6. Relationship between epidemiological effect size (log10OR) and frequency of causativemutations at two unlinked loci under two different
penetrance models. See legend to Fig 4 for details.
doi:10.1371/journal.pone.0132150.g006
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because the former will inevitably have the more comprehensive mutational spectrum. Indeed,
notwithstanding alternative explanations, our empirical observation of a negative correlation
between ORs and disease prevalence in published GWAS reports lends support to the validity
of this view because such a correlation would be predicted by the above mechanism of
confounding.
Since the described phenomenon of effect size obfuscation is due to a negative correlation
between causative mutations, it may be surmised that oligogenic and polygenic diseases would
be less likely to be affected, given the likelihood of recombination eradicating the necessary cor-
relations with time. However, our simulations of diseases etiologies involving up to 10 unlinked
loci indicate that this decay with gene number of the implied inter-mutation correlation may
be smaller than expected, which means that our findings are relevant to monogenic and oligo-
genic diseases alike and may, to some extent, even apply to polygenic diseases.
At first glance, the confounding of genotype-phenotype relationships by the underlying
gene genealogy may appear reminiscent of other, similarly counterintuitive phenomena. For
example, ‘synthetic association’ [13–16] conceptualizes the notion that a common non-causa-
tive genetic variant may become disease-associated due to the chance accumulation of rare
causative variants in cis. By contrast, the confounding mechanism described herein refers
exclusively to truly causative mutations and addresses their genealogy-actuated relationship.
Moreover, studies of synthetic association [13] so far have paid little attention to the effect sizes
of the rare (causative) variants but have instead focused mainly upon the common (non-causa-
tive) variant. ‘Flip-flop’ association [12] is another enigma that signifies a frequent reverting
Table 3. Spectrum of causative mutations at two unlinked loci under two different penetrancemodels.
Model parameters Median number of mutations (IQR)
Per population Per case Per control
Rare disease (prevalence: 0.1–1%)
Multiplicative
γ = 0.3 3 (2–5) 1.000 (1.000–1.000) 0.012 (0.007–0.019)
γ = 0.1 5 (3–7) 1.000 (1.000–1.029) 0.055 (0.029–0.077)
Logistic
α = -5; β = 1 5 (3–8) 0.384 (0.200–0.553) 0.172 (0.080–0.264)
α = -5; β = 0.5 9 (5–15) 0.854 (0.614–1.052) 0.616 (0.422–0.781)
Common disease (prevalence: 1–5%)
Multiplicative
γ = 0.3 5 (3–8) 1.018 (1.002–1.051) 0.079 (0.051–0.105)
γ = 0.1 8 (5–13) 1.130 (1.036–1.284) 0.364 (0.251–0.436)
Logistic
α = -5; β = 1 18 (13–25) 2.270 (2.040–2.480) 1.473 (1.268–1.645)
α = -5; β = 0.5 40 (29–54) 4.383 (4.145–4.609) 3.500 (3.253–3.709)
Pandemic disease (prevalence: 10–20%)
Multiplicative
γ = 0.3 10 (6–15) 1.240 (1.095–1.471) 0.453 (0.371–0.501)
γ = 0.1 22 (15–31) 2.426 (2.183–2.700) 1.879 (1.699–1.991)
Logistic
α = -5; β = 1 35 (26–46) 4.012 (3.772–4.311) 2.784 (2.547–3.007)
α = -5; β = 0.5 72 (56–93) 7.704 (7.424–8.036) 6.319 (6.002–6.567)
IQR: inter-quartile range
doi:10.1371/journal.pone.0132150.t003
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role of the risk allele in different studies of one and the same genotype-phenotype relationship.
Flip-flop associations are potentially explicable by chance differences in linkage disequilibrium
between different samples from the same population. Here, we repeatedly simulated a whole
population so that the ensuing disease prevalence, allele frequencies and potentially misleading
OR were true (population-wide) values, not estimates subject to sampling error. Confounding
by gene genealogy is also different from ‘indirect association’ [17] although the core ideas of
the two concepts partly overlap. Nevertheless, while indirect association focuses upon the con-
sequences of linkage disequilibrium and gene-gene interaction between a non-causative and a
causative variant, our analysis was concerned exclusively with causative mutations that become
subject to confounding themselves.
Our results imply that the functional follow-up of disease-associated genetic variants could
in some cases be misguided with the consequence that truly causative mutations might inad-
vertently and inappropriately be excluded from further investigation. While the protective
effect of a causative mutation may pose minor problems in terms of its initial statistical evalua-
tion, an OR<1 would be difficult to reconcile with the damaging character of the mutation in
subsequent bioinformatics analyses. Since expensive functional studies in vitro or in vivo usu-
ally require solid theoretical evidence for causality, such inconclusiveness is likely to be a major
deterrent to further research on the variant in question. A genealogy-actuated negative correla-
tion between causative mutations may also explain why many genotype associations with
Table 4. Proportion of epidemiologically protective mutations at two unlinked loci under two different penetrancemodels.
Model parameters Percentage mutations with OR<1.0 Percentage mutations with
OR>m or OR<1/m (percentage
of these with OR<1)
Percentage mutations with OR<1.0
among those with frequency <f
m = 1.5 m = 2.0 f = 0.001 f = 0.01 f = 0.05
Rare disease (prevalence: 0.1–1%)
Multiplicative
γ = 0.3 0.00 100.0 (0.00) 100.0 (0.00) 0.00 0.00 0.00
γ = 0.1 0.00 100.0 (0.00) 100.00 (0.00) 0.00 0.00 0.00
Logistic
α = -5; β = 1 2.85 90.54 (0.81) 78.51 (0.39) 0.00 0.00 3.78
α = -5; β = 0.5 12.33 68.97 (5.27) 44.17 (2.80) 0.00 0.00 14.02
Common disease (prevalence: 1–5%)
Multiplicative
γ = 0.3 0.00 99.96 (0.00) 99.86 (0.00) 0.00 0.00 0.00
γ = 0.1 0.78 97.35 (0.17) 93.76 (0.06) 0.00 1.57 1.07
Logistic
α = -5; β = 1 12.32 79.14 (6.47) 63.24 (3.98) 0.00 9.09 10.59
α = -5; β = 0.5 22.97 64.70 (14.50) 42.99 (10.67) 0.00 17.66 21.36
Pandemic disease (prevalence: 10–20%)
Multiplicative
γ = 0.3 1.25 96.38 (0.40) 90.48 (0.17) 3.84 2.44 1.71
γ = 0.1 14.78 64.35 (7.61) 39.38 (4.95) 11.88 17.86 15.58
Logistic
α = -5; β = 1 19.29 75.66 (13.32) 59.01 (10.09) 8.42 16.52 17.25
α = -5; β = 0.5 28.20 64.82 (21.39) 44.73 (17.55) 13.09 25.39 26.41
OR: odds ratio
doi:10.1371/journal.pone.0132150.t004
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complex diseases have often been difficult to replicate, because the identity, frequency and
degree of association of the negatively correlated causative mutations are likely to differ
between populations. Consistent with this postulate, several disease associations reported in
the literature have been with different variants in the respective discovery and replication anal-
yses [32–36].
Our results suggest that many causative mutations are unlikely to be identified by associa-
tion analysis based upon case-control comparisons, thereby rendering questionable the fre-
quent claim that the success prospects of GWAS depend heavily upon sample size [2].
Moreover, great store has been set by employing next-generation sequencing (NGS) to identify
rare, and therefore potentially younger, causative mutations. Some current strategies for the
statistical analysis of NGS data aim to detect genes that are enriched in mutations in cases as
compared to controls [37–43]. As has been shown here, such a strategy could be seriously com-
promised, particularly for common and pandemic diseases, if a certain threshold number of
mutations were to be required for the functionality of a relevant gene to be sufficiently
impaired to yield a clinical phenotype [19]. One possible way out of this dilemma could be to
incorporate population genealogy more explicitly into the statistical evaluation of NGS data,
either analytically or by way of simulation. Indeed, the development of the necessary methodol-
ogy may well constitute an interesting new field of future genetic epidemiological research. Fur-
thermore, one way to identify candidate variants for a genealogy-actuated negative correlation
would be to search for apparently protective variants that have been subject to negative
Fig 7. Observed proportion of epidemiologically protective causative mutations vs. number of unlinked loci underlying disease etiology. Bold solid
line: pandemic disease (prevalence 10%-20%); Thin solid line: common disease (1%-5%); Dashed line: rare disease (0.1%-1.0%). (A) Multiplicative model
with parameter value γ = 0.3 (blue) or γ = 0.1 (red). (B) Logistic model with parameter values α = -5; β = 1 (blue) or α = -5; β = 0.5 (red).
doi:10.1371/journal.pone.0132150.g007
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selection or conversely, apparent risk variants that have been subject to positive selection.
Finally, it is worthy of note that linkage-based genetic epidemiological studies would not be
affected by the confounding phenomenon described here because they exploit the co-segrega-
tion of genotypes and phenotypes in families rather than their co-occurrence in unrelated
individuals.
Although the coalescent is the method of choice to model gene genealogies, the many
assumptions made in coalescence theory have prompted some criticism of the approach [23].
Fig 8. Effect size (log10OR) of trait-associated genetic variants vs. trait prevalence. The analysis was based upon data for 31 traits from the GWAS
catalogue. Grey dots: trait-specific effect size (log10OR) in the GWAS catalogue with reported prevalence between 0.1 and 20% (i.e. 1834 associations with
p<5x10-4); blue dots: median log10OR per trait; red line: linear regression line for log10OR versus trait prevalence (p<10
−15); blue line: linear regression line
for median log10OR versus trait prevalence (p = 0.049).
doi:10.1371/journal.pone.0132150.g008
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In particular, the basic coalescent used in our study is valid only for an idealized population,
i.e. one with non-overlapping generations, constant size, randommating and a lack of selection
and recombination [22]. In reality, these assumptions are rarely if ever met. Thus, future stud-
ies of the confounding phenomenon described herein may well wish to adopt more complex
genealogy models, although we expect our conclusions to remain largely unchanged. For exam-
ple, the Moran model allows for overlapping generations although it can reasonably be approx-
imated by the basic coalescent via an adjustment of the time scale [22]. Consideration of
population growth would lead to shorter branches at the root and longer branches at the tips of
the coalescence tree [22,44] but the possibility of a negative correlation between causative
mutations would still remain. The same is true for population structure, which may even exac-
erbate the described phenomenon because population structure tends to promote the separa-
tion of younger mutations in a genealogical tree. We would also maintain that, in view of the
multifactorial nature of many common diseases, selection of single causative mutations is likely
to have been weak up to the point that some deleterious mutations could have become fixed in
human evolution at a rate similar to that of neutral variation [45]. Therefore, selection may be
neglected here, at least for common and pandemic diseases where the impact of a single causa-
tive mutation on biological fitness is expected to be minor. Finally, models taking recombina-
tion into account would allow the investigation of larger genes or gene regions. However, the
simulations would become much more complicated because a recombination coalescent com-
prises random graphs instead of a random tree [23], and it is unclear whether this additional
level of complexity would qualitatively change our conclusions.
The same effect size was assumed in our simulations for frequent and rare mutations.
Although rare mutations with strong effects undoubtedly would be easier to detect through
association studies (e.g. [46]), this does not preclude the possibility that in reality many rare
variants also exert only modest effects. Consequently, assuming equal effect sizes for rare and
frequent variants is not uncommon for simulation studies in genetic epidemiology (e.g. [26]).
Furthermore, whilst the total population number of causative mutations in our study may
appear somewhat high under some scenarios, these numbers nevertheless recall the shift in
mutation-drift equilibrium towards an accumulation of rare variants in recent human history
[47]. Indeed, substantial heterogeneity of causative alleles at a single disease locus is not
uncommon even for monogenic subtypes of human diseases, including breast cancer due to
BRCA1mutations [48,49].
Our consideration of pairs or groups of unlinked loci revealed that the proportion of appar-
ently protective mutations arising along a given genealogy is only slightly smaller than for a
single locus, which implies that recombination should only slightly affect the potential for con-
founding described herein. Moreover, although our simulations were confined to haploid loci,
it is important to note that diploid inheritance is equally likely to suffer from the described
decoupling of causality and the epidemiological effect size of individual mutations.
Finally, it could be argued that higher disease prevalence would automatically lead to larger
samples so that variants with small effect size should not be missed particularly for common or
pandemic diseases. The truth of this assertion notwithstanding, sample size seems to be of
minor relevance in the present context because, even for a disease with 0.1% prevalence, a
medium-sized population of 40 million (i.e. still smaller than that of the UK, France or Ger-
many, which have been a strong focus of GWAS) would still contain at least 40,000 cases.
Thus, prevalence is not a rate limiting factor for achieving the usual GWAS sample sizes of
3000 to 5000 cases.
In conclusion, genetic studies of common human diseases should take into account the pos-
sibility that some causative genetic variants could pose as protecting rather than predisposing
in classical case-control comparisons. In cases of discordant epidemiological and
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bioinformatics evidence, both (or all alleles) of a significantly associated variant should be con-
sidered putatively causative in functional follow up analyses. Moreover, collapsing of rare vari-
ants from next-generation sequencing in case-control studies should be done with great care,
acknowledging the fact that the opposing effects of truly causative mutations may cancel out.
Finally, it may well be that we shall have to come to terms with the fact that some mutations
causing complex human disease are inherently unidentifiable ab initio by case-control associa-
tion studies.
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